NF-kB as a potential prognostic marker and a candidate for targeted therapy of cancer


  • K.A. Gaptulbarova Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Science
  • M.M. Tsyganov Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Science
  • A.M. Pevzner Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Science
  • M.K. Ibragimova Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences
  • N.V. Litviakov Research Institute of Oncology, Tomsk National Research Medical Center of the Russian Academy of Sciences



homologous recombination deficiency, marker, NF-kB1, personalized medicine


Summary. The NF-kB1 gene belongs to the family of transcription factors that are involved in the regulation of a wide range of biological reactions. It has been established that NF-kB1 plays an important role in the regulation of immune responses, but more and more studies indicate that this gene is involved in the processes of oncogenesis and DNA repair. The product of this gene regulates the expression of genes involved in the development and progression of cancer. In recent years, numerous studies have been aimed at elucidating the functional consequences of the activation of NF-kB1, as well as its signaling mechanisms. In this regard, NF-kB1 is an interesting therapeutic target for a possible personalized approach in the treatment of cancer. This article provides an overview of modern clinical studies of the NF-kB1 gene, which acts as a predictive and prognostic marker in the treatment of cancer.


Héron E, Deloukas P, Van Loon AP. The complete exon-intron structure of the 156-kb human gene NF-kB1, which encodes the p105 and p50 proteins of transcription factors NF-κB and IκB-γ: implications for NF-κB-mediated signal transduction. Genomics 1995; 30: 493–505.

Dakubo GD. Molecular Pathology of Cancer, in: Cancer Biomarkers in Body Fluids. Springer International Publishing: Switzerland 2016, pp. 1–54.

Baldwin Jr AS. The NF-κB and IκB proteins: new discoveries and insights. Ann Rev Immunol 1996; 14: 649–81.

Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell 1986; 46: 705–16.

Cartwright T, Perkins ND, Wilson CL. NFKB1: a suppressor of inflammation, ageing and cancer. The FEBS Journal 2016; 283: 1812–22.

Kaileh M, Sen R. NF-κB function in B lymphocytes. Immunol Rev 2012; 246: 254–71.

Stepanova EV, Abramov ME, Lichinicer MR. NF-kB signaling disruption: clinical application. Rus J Biother 2010; 9: 27–30 (in Russian).

Concetti J, Wilson C. NFKB1 and cancer: friend or foe? Cells 2018; 7: 1–16.

Sasaki N, Morisaki T, Hashizume K, et al. Nuclear factor-κB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 2001; 7: 4136–42.

Ye S, Long Y-M, Rong J, et al. Nuclear factor kappa B: a marker of chemotherapy for human stage IV gastric carcinoma. World J Gastroenterol 2008; 14: 4739–44.

Guo RX, Qiao YH, Zhou Y, et al. Increased staining for phosphorylated AKT and nuclear factor-κB p65 and their relationship with prognosis in epithelial ovarian cancer. Pathol Intern 2008; 58: 749–56.

Telli ML, Hellyer J, Audeh W, et al. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Research Treat 2018; 168: 625–30.

Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014; 20: 764–75.

Litvyakov NV, Cherdyntseva NV, Tsyganov MM, et al. Influence of gene polymorphismon the expression of the multidrug resistance genes in breast tumor during neoadjuvant chemotherapy. Med Genetics 2011; 10: 37–43 (in Russian).

Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010; 10: 293–301.

Sau A, Lau R, Cabrita MA, et al. Persistent activation of NF-κB in BRCA1-deficient mammary progenitors drives aberrant proliferation and accumulation of DNA damage. Cell Stem Cell 2016; 19: 52–65.

Harte MT, Gorski JJ, Savage KI, et al. NF-κB is a critical mediator of BRCA1-induced chemoresistance. Oncogene 2014; 33: 713–23.

Staudt LM. Oncogenic activation of NF-κB. Cold Spring Harbor Perspect Biol 2010; 2: 1–31.

Gershtein E, Scherbakov A, Platova A, et al. Expression and activity of the nuclear transcription factor NF-carr B, its inhibitor 1kBα and protein kinase Akt1 in tumors of patients with breast cancer. Clin Med Almanac 2010; 1: 55–60 (in Russian).

Tak PP, Firestein GS. NF-κB: a key role in inflammatory diseases. J Clin Invest 2001; 107: 7-11.

Piotrowska A, Iżykowska I, Podhorska-Okołów M, et al. Budowa białek z rodziny NF-kB i ich rola w procesie apoptozy [The structure of NF-kB family proteins and their role in apoptosis]. Postepy Hig Med Dosw 2008; 62: 64–74 (in Polish).

Ghosh S, Gifford AM, Riviere LR, et al. Cloning of the p50 DNA binding subunit of NF-kB: homology to rel and dorsal. Cell 1990; 62:1019–29.

Kieran M, Blank V, Logeat F, et al. The DNA binding subunit of NF-kB is identical to factor KBF 1 and homologous to the rel oncogene product. Cell 1990; 62: 1007–18.

Ruben S, Dillon P, Schreck R, et al. Isolation of a rel-related human cDNA that potentially encodes the 65-kD subunit of NF-kB. Science 1991; 251: 1490–3.

Ryseck R-P, Bull P, Takamiya M, et al. RelB, a new Rel family transcription activator that can interact with p50-NF-kB. Mol Cell Biol 1992; 12: 674–84.

May MJ, Ghosh S. Rel/NF-κB and IκB proteins: an overview. Semin Cancer Biol 1997; 2: 63–73.

Chen F. NF-kB1 (nuclear factor of kappa light polypeptide gene enhancer in B-cells 1). Atlas Genet Cytogenet Oncol Haematol 2002; 1: 94–5.

Lee SH, Hannink M. Characterization of the nuclear import and export functions of IkB. J Biol Chem 2002; 277: 23358–66.

Sun SC. The non-canonical NF-κB pathway in immunity and inflammation. Nat Rev Immunol 2017; 17: 545–555.

Deptała A, Nurzyńska D, Darżynkiewicz Z, et al. Rola białek z rodziny Rel/NFkB/IkB w patogenezie nowotworów. Post Biol Kom 2002; 29: 489–504 (in Polish).

Moynagh PN. The NF-kB pathway. J Cell Sci 2005; 118: 4589–92.

Li Z, Nabel GJ. A new member of the I kappaB protein family, I kappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription. Mol Cell Biol 1997; 17: 6184–90.

Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nature Rev Mol Cell Biol 2007; 8: 49–62.

Park M, Hong J. Roles of NF-κB in cancer and inflammatory diseases and their therapeutic approaches. Cells 2016; 5: 1–13.

Karin M, Delhase M. The IκB kinase (IKK) and NF-κB: key elements of proinflammatory signalling. Semin Immunol 2000; 12: 85–98.

Novikov DG, Kononov AV. The role of nuclear factor κB in the development of chronic gastritis and gastrointestinal cancer. Bull NSU 2010; 8: 149–58 (in Russian).

Lin L, Demartino GN, Greene WC. Cotranslational biogenesis of NF-κB p50 by the 26S proteasome. Cell 1998; 92: 819–28.

Plewka A, Madej P, Plewka D, et al. Immunohistochemical localization of selected pro-inflammatory factors in uterine myomas and myometrium in women of various ages. Folia Histochem Cytobiol 2013; 51: 73–83.

Li F, Sethi G. Targeting transcription factor NF-κB to overcome chemoresistance and radioresistance in cancer therapy. Biochim Biophys Acta Rev Cancer 2010; 1805: 167–80.

Russo SM, Tepper JE, Baldwin Jr AS, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int J Rad Oncol Biol Phys 2001; 50: 183–93.

Begg AC. Predicting recurrence after radiotherapy in head and neck cancer. Semin Rad Oncol 2012; 22: 108–18.

Prakash R, Zhang Y, Feng W, et al. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harbor Persp Biol 2015; 7: 1–29.

Xu X, Weaver Z, Linke SP, et al. Centrosome amplification and a defective G2–M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform–deficient cells. Mol Cell 1999; 3: 389–95.

Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2009; 115: 359–63.

Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481: 287–94.

Durkacz BW, Omidiji O, Gray DA, et al.,(ADP-ribose) n participates in DNA excision repair. Nature 1980; 283: 593–6.

Wu JT, Kral JG. The NF-κB/IκB signaling system: a molecular target in breast cancer therapy. J Surg Res 2005; 123: 158–69.

Buckley NE, Haddock P, Simoes RDM, et al. A BRCA1 deficient, NFκB driven immune signal predicts good outcome in triple negative breast cancer. Oncotarget 2016; 7: 19884–96.

Schmidt M, Madjar K, Heimes A, et al. Prognostic significance of nuclear factor kappa B in node-negative breast cancer is most pronounced in luminal B breast cancer. AACR 2017; 77: P2–5.

Kim J-Y, Jung HH, Ahn S, et al. The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment. Sci Rep 2016; 6: 1–11.

Dalmases A, González I, Menendez S, et al. Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer. Oncotarget 2014; 5: 196–210.

Ghosh CC, Ramaswami S, Juvekar A, et al. Gene-specific repression of proinflammatory cytokines in stimulated human macrophages by nuclear IκBα. J Immunol 2010; 185: 3685–93.

Antoon JW, White MD, Slaughter EM, et al. Targeting NFκ B mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 2011; 11: 678–89.

Hinohara K, Kobayashi S, Kanauchi H, et al. ErbB receptor tyrosine kinase/NF-κB signaling controls mammosphere formation in human breast cancer. Proc Natl Acad Sci USA 2012; 109: 6584–9.

Zhou Y, Yau C, Gray JW, et al. Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007; 7: 1–15.

Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC. The NFκB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 2005; 12: S37–46.

Dzhugashvili M, Luengo-Gil G, García T, et al. Role of genetic polymorphisms in NFKB-mediated inflammatory pathways in response to primary chemoradiation therapy for rectal cancer. Int J Rad Oncol Biol Phys 2014; 90: 595–602.

Varga G, Mikala G, Andrikovics H, et al. NFKB 1−94ins/del ATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma. Br J Haematol 2015; 168: 679–88.

Meylan E, Dooley AL, Feldser DM, et al. Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma. Nature 2009; 462: 104–7.

Yurmazov ZA, Spirina LV, Usynin EA, et al. Molecular indicators related to the effectiveness of everolimus therapy in patients with disseminated kidney cancer. Sib J Oncol 2016; 15: 42–7 (in Russian).

Sweeney CJ, Mehrotra S, Sadaria MR, et al. The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther 2005; 4: 1004–12.

Ho WC, Dickson KM, Barker PA. Nuclear factor-κB induced by doxorubicin is deficient in phosphorylation and acetylation and represses nuclear factor-κB–dependent transcription in cancer cells. Cancer Res 2005; 65: 4273–81.

Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA (p65) NF-κB. Mol Cell 2004; 13: 853–65.

Montagut C, Tusquets I, Ferrer B, et al. Activation of nuclear factor-κ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Rel Cancer 2006; 13: 607–16.

Dalmases A, González I, Menendez S, et al. Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer. Oncotarget 2014; 5: 196–210.

Palombella VJ, Rando OJ, Goldberg AL, et al. The ubiquitinproteasome pathway is required for processing the NF-κB1 precursor protein and the activation of NF-κB. Cell 1994; 78: 773–85.

Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl J Med 2005; 352: 2487–98.

Liu S, Liu Z, Xie Z, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-κB–dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008; 111: 2364–73.

Schmid P, Kühnhardt D, Kiewe P, et al. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol 2008; 19: 871–6.




How to Cite

Gaptulbarova, K., Tsyganov, M., Pevzner, A., Ibragimova, M., & Litviakov, N. (2023). NF-kB as a potential prognostic marker and a candidate for targeted therapy of cancer. Experimental Oncology, 42(4), 263–269.

Most read articles by the same author(s)